-

Shareholder Alert: Robbins LLP Reminds Investors That Splunk, Inc. (SPLK) is Being Sued for Misleading Shareholders

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Splunk, Inc. (NASDAQ: SPLK) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between October 21, 2020 and December 2, 2020. Splunk develops and markets software solutions that enable organizations to gain real-time organizational intelligence in the U.S. and internationally.

If you suffered a loss due to Splunk Inc.'s misconduct, click here.

Splunk, Inc. (SPLK) Misled Shareholders About its Third Quarter 2021 Financial Results

According to the complaint, on October 21, 2020, Splunk held a call with several analysis at the Virtual Analyst & investor Session at conf.20. During the call, Splunk assured investors that everything was on track for its third quarter 2021 financial results. However, after the markets closed on December 2, 2020, Splunk announced disappointing results for its third quarter 2021, including an 11% decrease in total revenues, which missed estimated by nearly $60 million. On an earnings call the same day, Splunk admitted that despite reiterating its 2021 third quarter guidance just 10 days before the close of the quarter, the results fell "short of both our expectation and our communication of those expectations." On this news, JPMorgan announced it was "blindsided by the magnitude of too many large details slipping in the final days of October." Shares of Splunk plummeted, closing down over 24% on December 3, 2020. Shareholders later learned that Splunk had failed to disclose it was not closing deals with its largest customers and was not hitting the financial targets it had previously announced.

Purchasers of Splunk, Inc. (SPLK) securities have until February 2, 2021, to ask the court to appoint them as lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Splunk, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom